Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI.
Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Zhou Z, et al. Among authors: scoggins me. Sci Rep. 2023 Jan 20;13(1):1171. doi: 10.1038/s41598-023-27518-2. Sci Rep. 2023. PMID: 36670144 Free PMC article.
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.
Rauch GM, Kuerer HM, Scoggins ME, Fox PS, Benveniste AP, Park YM, Lari SA, Hobbs BP, Adrada BE, Krishnamurthy S, Yang WT. Rauch GM, et al. Among authors: scoggins me. Breast Cancer Res Treat. 2013 Jun;139(3):639-47. doi: 10.1007/s10549-013-2598-7. Epub 2013 Jun 18. Breast Cancer Res Treat. 2013. PMID: 23774990 Free PMC article.
Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence.
Rauch GM, Hobbs BP, Kuerer HM, Scoggins ME, Benveniste AP, Park YM, Caudle AS, Fox PS, Smith BD, Adrada BE, Krishnamurthy S, Yang WT. Rauch GM, et al. Among authors: scoggins me. Ann Surg Oncol. 2016 Feb;23(2):482-9. doi: 10.1245/s10434-015-4876-6. Epub 2015 Sep 28. Ann Surg Oncol. 2016. PMID: 26416712 Free PMC article.
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.
Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. Litton JK, et al. NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 29238749 Free PMC article.
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Litton JK, et al. Among authors: scoggins me. J Clin Oncol. 2020 Feb 10;38(5):388-394. doi: 10.1200/JCO.19.01304. Epub 2019 Aug 28. J Clin Oncol. 2020. PMID: 31461380 Free PMC article. Clinical Trial.
36 results